{
     "PMID": "27875747",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20180103",
     "LR": "20180211",
     "IS": "1872-6844 (Electronic) 0920-1211 (Linking)",
     "VI": "129",
     "DP": "2017 Jan",
     "TI": "New model of pharmacoresistant seizures induced by 3-mercaptopropionic acid in mice.",
     "PG": "8-16",
     "LID": "S0920-1211(16)30250-9 [pii] 10.1016/j.eplepsyres.2016.10.012 [doi]",
     "AB": "About 30% of the patients with epilepsy do not respond to clinically established anticonvulsants, despite having effective concentrations of the antiepileptic drug in plasma. Therefore, new preclinical models of epilepsy are needed to identify more efficacious treatments. We describe here a new drug-resistant seizure model in mice to be used at the early stages of pre-clinical trials. This model consists in inducing daily generalized seizures for 23 consecutive days by administration of 3-mercaptopropionic acid (MP). As a result, 100% of animals become resistant to phenytoin and 80% to phenobarbital. Such resistance is strongly associated with the overexpression of P-glycoprotein (Pgp), observed in cerebral cortex, hippocampus and striatum while resistance to Pgp nonsubstrate drugs such as carbamazepine, diazepam and levetiracetam is not observed. This model could be useful for screening novel anticonvulsant drugs with a potential effect on pharmacoresistant seizures treatment.",
     "CI": [
          "Copyright (c) 2016 Elsevier B.V. All rights reserved."
     ],
     "FAU": [
          "Enrique, Andrea",
          "Goicoechea, Sofia",
          "Castano, Rocio",
          "Taborda, Facundo",
          "Rocha, Luisa",
          "Orozco, Sandra",
          "Girardi, Elena",
          "Bruno Blanch, Luis"
     ],
     "AU": [
          "Enrique A",
          "Goicoechea S",
          "Castano R",
          "Taborda F",
          "Rocha L",
          "Orozco S",
          "Girardi E",
          "Bruno Blanch L"
     ],
     "AD": "Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina; Instituto de Biologia Celular y Neurociencia \"Prof. Eduardo De Robertis\", Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Facultad de Medicina. Universidad de Buenos Aires, Buenos Aires, Argentina. Electronic address: andreaenrique@biol.unlp.edu.ar. Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina. Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina. Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina. Departamento de Farmacobiologia, Centro de Investigaciones y Estudios Avanzados, Tlalpan, DF, Mexico. Unidad de Investigaciones Medicas en Enfermedades Neurologicas, Centro Medico Nacional, Cuauhtemoc, DF, Mexico. Instituto de Biologia Celular y Neurociencia \"Prof. Eduardo De Robertis\", Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Facultad de Medicina. Universidad de Buenos Aires, Buenos Aires, Argentina. Laboratorio de Investigacion y Desarrollo de Bioactivos (LIDeB), Departamento de Ciencias Biologicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20161027",
     "PL": "Netherlands",
     "TA": "Epilepsy Res",
     "JT": "Epilepsy research",
     "JID": "8703089",
     "RN": [
          "0 (ATP-Binding Cassette, Sub-Family B, Member 1)",
          "0 (Anticonvulsants)",
          "6158TKW0C5 (Phenytoin)",
          "B03TJ3QU9M (3-Mercaptopropionic Acid)",
          "YQE403BP4D (Phenobarbital)"
     ],
     "SB": "IM",
     "MH": [
          "*3-Mercaptopropionic Acid",
          "ATP-Binding Cassette, Sub-Family B, Member 1/metabolism",
          "Animals",
          "Anticonvulsants/pharmacology",
          "Blotting, Western",
          "Cerebral Cortex/drug effects/metabolism/pathology",
          "Corpus Striatum/drug effects/metabolism/pathology",
          "*Disease Models, Animal",
          "*Drug Resistant Epilepsy/drug therapy/metabolism/pathology",
          "Hippocampus/drug effects/metabolism/pathology",
          "Immunohistochemistry",
          "Male",
          "Mice",
          "Phenobarbital/pharmacology",
          "Phenytoin/pharmacology",
          "Random Allocation",
          "*Seizures/drug therapy/metabolism/pathology"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "*3-Mercaptopropionic acid",
          "*Animal models",
          "*Drug resistance",
          "*Mice",
          "*P-glycoprotein",
          "*Refractory epilepsy"
     ],
     "EDAT": "2016/11/23 06:00",
     "MHDA": "2018/01/04 06:00",
     "CRDT": [
          "2016/11/23 06:00"
     ],
     "PHST": [
          "2016/06/06 00:00 [received]",
          "2016/10/07 00:00 [revised]",
          "2016/10/24 00:00 [accepted]",
          "2016/11/23 06:00 [pubmed]",
          "2018/01/04 06:00 [medline]",
          "2016/11/23 06:00 [entrez]"
     ],
     "AID": [
          "S0920-1211(16)30250-9 [pii]",
          "10.1016/j.eplepsyres.2016.10.012 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Epilepsy Res. 2017 Jan;129:8-16. doi: 10.1016/j.eplepsyres.2016.10.012. Epub 2016 Oct 27.",
     "term": "hippocampus"
}